Global Soft Tissue Repair Market

Biotechnology Services Market Definition

The biotechnology services market consists of the sales of biotechnology services and related goods by entities (organizations, sole traders, and partnerships) that engage in conducting research and experimental development in biotechnology. Biotechnology develops or creates different products utilizing living organisms, parts, or biological systems. The applications of biotechnology include therapeutics, diagnostics, agricultural genetically modified crops, bioremediation, processed food, energy production and waste treatment. The market covered in this report includes sales of biotechnology services by clinical research organizations (CROs), contract manufacturers organizations (CMOs), and contract research and manufacturing services (CRAMS) to bio-pharmaceutical, food biotechnology, academic and other end customer companies.

Regenerative Medicine Market Definition

The regenerative medicine market consists of sales of regenerative medicines by entities (organizations, sole traders, and partnerships) that make products that are used to replace tissue or organs that have been damaged by disease, trauma, or congenital issues. The main objective of regenerative medicines is to replace the tissues which are damaged by disease, injury, age, or other issues instead of treating symptoms with medication and procedures. Regenerative medicine is a branch of medicine that develops methods to regrow, repair or replace damaged or diseased cells, tissues or organs. Regenerative medicine includes the generation and use of therapeutic stem cells, tissue engineering and the production of artificial organs. The regenerative medicines are essential when chronic diseases such as stroke, heart attacks, diabetes, and Alzheimer affects the human body with loss of cells such as neurons , cardiac muscle, and pancreatic beta cells.

Prosthetic heart valve devices and equipment are artificial heart valves that are implanted in the heart of a patient with valvular heart disease. The main types of prosthetic heart valve devices and equipment are transcatheter heart valve, tissue heart valve, and mechanical heart valve. Transcatheter aortic valve replacement is an invasive heart procedure to replace a thickened aortic valve that will not fully open. The product types are repair products, mitral valve repair devices, and tricuspid valve repair devices. The technologies involved in prosthetic heart valve devices and equipment are biological valves and decellularized valves that are used in various applications such as hospitals and ambulatory surgery centres. The prosthetic heart valve devices and equipment market research report is one of a series of new reports from The Business Research Company that provides prosthetic heart valve devices and equipment market statistics, including prosthetic heart valve devices and equipment industry global market size, regional shares, competitors with a prosthetic heart valve devices and equipment market share, detailed prosthetic heart valve devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the prosthetic heart valve devices and equipment industry. This prosthetic heart valve devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global prosthetic heart valve devices and equipment market size will grow from $5.04 billion in 2022 to $5.5 billion in 2023 at a compound annual growth rate (CAGR) of 9.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The prosthetic heart valve devices and equipment market size is expected to grow to $7.41 billion in 2027 at a CAGR of 7.7%. The rising prevalence of valvular heart disease has driven the need for transcatheter aortic valve replacement (TAVR) procedures, thus driving the prosthetic heart valve devices and equipment market. TAVR is a minimally-invasive surgical procedure done to cure aortic stenosis which is a valvular heart disease that affects the aortic valve of the heart. Aortic stenosis affects the aortic valve by hardening it, thus not allowing blood to properly flow through it and TAVR is used to replace this defective aortic valve with a transcatheter valve. According to a report from The Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) TVT Registry, volumes have grown every year. In 2021, TAVR procedures make up more than 84% of aortic valve replacement procedures in the united states. 92,000 TAVR procedures were done in 2021. As the rate of occurrence of valvular heart diseases rises, the number of TAVR procedures done can be expected to increase which also increases the demand for transcatheter valves, thus driving the market going forward. Prosthetic heart valve devices have stringent procedures for approval which restrains the growth of the prosthetic heart valve devices and equipment market. According to the US food and drugs administration (FDA), randomized clinical trials are required for any medical device, to test for its safety standards. A randomized clinical trial is a clinical method of study that involves the separation of groups of patient subjects using random selection. This is done to compare different medicines and treatment methods fairly with no room for bias and also to detect side effects if any. However, these random clinical trials take long periods. Companies in this market are increasingly preferring polymer valves over traditional mechanical and bio-prosthetic valves/tissue valves. Polymer heart valves are prosthetic heart valves made of polymeric materials and have better functioning than tissue and mechanical heart valves. Mechanical heart valves come with a lifelong requirement of using blood-thinning medication to prevent blood clotting whereas bioprosthetic heart valves come with a short life span that needs several replacements and have a risk of valve degradation. Polymeric heart valves on the other hand support better blood flow and reduce the risk of blood clotting and therefore do not have the disadvantages of tissue and mechanical valves. Therefore, various companies are focusing on the development of polymeric heart valve technologies, For instance, in July 2022, Shanghai Medics, a Shanghai-based medical technology company developed new synthetic heart valve. The new valve is developed using polymer nanomaterial and has a longer lasting life of 20 to 25 years. The prosthetic heart valve devices and equipment market is monitored by regulatory bodies such as FDA in the US and The Central Drugs Standard Control Organization (CDSCO). For instance, CDSCO issued a notice regarding the classification of the risk levels of different medical devices. Under this classification, prosthetic heart valves are considered a class D or high-risk device. Similarly, for manufacturers to produce and sell prosthetic valve devices in India, they need to sign forms MD-7 and MD-8 which come under the direct purview of the central government of India. Form MD-7 is used to register prosthetic valve manufacturers in India and form MD-8 is used by prosthetic valve manufacturers to apply for loans. Major players in the prosthetic heart valve devices and equipment market are Boston Scientific, Edward life sciences, Medtronic, Livanova, Abbott, Jenavalve technology, Lepu medical, Cryolife, Neovasc Inc., and St. Jude medical. North America was the largest region in global prosthetic heart valve devices and equipment market in 2022. Western Europe was the second-largest region in prosthetic heart valve devices and equipment market. The regions covered in the global prosthetic heart valve devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the prosthetic heart valve devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The prosthetic heart valve devices and equipment market consist of sales of mechanical heart valves, transcatheter heart valves, and tissue heart valves that are used for heart patients. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global prosthetic heart valve devices and equipment market is segmented - 1) By Type: Transcatheter Heart Valve, Tissue Heart Valve,  Mechanical Heart Valve 2) By Application: Hospitals, Ambulatory Surgery Centres 3) By Product Type: Repair Products, Mitral Valve Repair Devices, Tricuspid Valve Repair Devices 4) By Technology: Biological Valve, Decellularized Valve

Biotechnology services refer to the services that modify living microorganisms to provide biotechnology products on a contract or custom basis to medical, pharmaceutical, and scientific laboratories. They provide breakthrough products and technologies to combat debilitating and rare diseases, reduce our environmental footprint, feed the hungry, use less and cleaner energy, and have safer, cleaner and more efficient industrial manufacturing processes. The main types of biotechnology services are prevention and disease control; public engagement activities; health education and research; food biotechnology services; donor recruitment; tissue collection; cell processing and isolation; and research and development. Food biotechnology services encompass a diverse variety of technologies used in crops, livestock, forestry, fisheries and aquaculture, and agro-industry. They are used for a variety of purposes, including genetic improvement of plants and animals to increase yields or efficiency, characterization and conservation of genetic resources for food and agriculture, plant and animal disease diagnosis, vaccine development, and fermented food production. The various applications include pharmaceutical, biotechnological, academic, clinical trial, and healthcare sectors and are used by Clinical Research Organizations (CROs), Contract Manufacturers Organizations (CMOs), and Contract Research and Manufacturing Services (CRAMS). The biotechnology services market research report is one of a series of new reports from The Business Research Company that provides biotechnology services market statistics, including biotechnology services industry global market size, regional shares, competitors with a biotechnology services market share, detailed biotechnology services market segments, market trends and opportunities, and any further data you may need to thrive in the biotechnology services industry. This biotechnology services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global biotechnology services market size will grow from $146.85 billion in 2022 to $163.71 billion in 2023 at a compound annual growth rate (CAGR) of 11.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global biotechnology services market size is expected to grow to $241.17 billion in 2027 at a CAGR of 10.2%. The increasing pervasiveness of conditions like hepatitis B, diabetes, and cancer is driving research in biotechnology. Biotechnology uses research tools from biology and chemistry to study the genetic material of bacteria and viruses to check the disease-producing agents. Oncology research is most prominent among biopharma companies. Stem cell treatment using a monoclonal antibody for therapy and genome sequencing is progressing in medical applications. According to the Indian Economic Survey 2021, the Indian biotechnology business is predicted to grow to US$ 150 billion by 2025. Global R&D spending by the world's largest publicly traded biotech companies increased by 13.7 percent each year, from $4.8 billion in 2001 to $55.0 billion in 2020. Therefore, the rising pervasiveness of diseases and huge expenses on R&D are predicted to contribute to the growth of the biotechnology services market. The risk related to genetic data is anticipated to limit the growth of the biotechnology services market. The biotechnological approach of transferring specially created genes for modification in characteristics to create genetically modified organisms (GMOs) has always been considered a threat to human and environmental health. According to the report of the World Conservation Union, there are numerous environmental risks likely to occur due to the use of GMOs, which include interbreeding, antibiotic resistance, impact on the ecosystem, creation of new or worse viruses, competition with natural species, unpredictable and unintended effects, and ethical concerns. The World Health Organization (WHO) has also set guidelines for manufacturers of GMO food. The National Bioengineered Food Disclosure Standard has been implemented in the USA since January 2020, making it mandatory to label all foods containing genetically engineered items as "bioengineered". Thus, the risk associated with genetically modified items is negatively impacting the growth of the biotechnology services market. Collaborations and partnerships between industry players are a growing trend in the field of biotech services. In January 2021, Novartis, a Switzerland-based pharmaceutical company collaborated with Alnylam, a US-based biopharmaceutical company for exploration in the application of the latter’s siRNA technology and the development of targeted therapy for the restoration of liver function. As part of the exclusive three-year research collaboration, Alnylam will develop and test potential siRNAs using Novartis' target-specific assays. Novartis will conduct further development and clinical research once a lead candidate has been identified. In October 2021, Amgen, a US-based biopharmaceutical company, acquired all outstanding shares of Teneobio for a deal amount of $2.5 billion. Amgen acquired Teneobio's bispecific and multispecific antibody technologies as part of the acquisition. These solutions complement the company's existing antibody expertise and BiTE platform. This will aid in the discovery and advancement of novel molecules for the treatment of a wide range of illnesses in Amgen's major treatment areas. TeneoBio is a US-based biotechnology business that specialises in the production of human heavy chain antibodies. Major players in the biotechnology services market are Novartis, Fisher BioService, Pfizer, Novo Nordisk, BioAlps, Precision for Medicine, Sartorius and Aldevron. Asia-Pacific was the largest region in the biotechnology services market in 2022. North America was the second largest region in the global biotechnology services market. The regions covered in the global biotechnology services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the biotechnology services market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The biotechnology services market consists of revenue earned by entities that engage in conducting research and experimental development in biotechnology. Numerous global issues are helped by biotechnology, including infectious diseases, ageing societies, food security, energy security, and climate change, to name a few. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products. The global biotechnology services market is segmented - 1) By Service: Prevention and Disease Control, Public Engagement Activities, Health Education and Research, Food Biotechnology Services, Donor Recruitment, Tissue Collection, Cell Processing and Isolation, Research and Development 2) By Industry: Clinical Research Organizations (CROs), Contract Manufacturers Organizations(CMOs), Contract Research and Manufacturing Services (CRAMS) 3) By Area of Application: Pharmaceutical, Biotechnological, Academic, Clinical Trial, Healthcare Sectors

The facial tissues refers to tissue papers or wipes or paper handkerchiefs that are thin, soft, absorbent, smooth, and disposable which are used for cleaning the face and reducing the spread of an infection or diseases as like swine flu. They serve as disposable alternatives to handkerchiefs made of cloth. The main types of facial tissues are box facial tissue and pocket facial tissues. Pocket facial tissues are soft, absorbent, disposable papers used for the cleansing of the face available in small packs. It is distributed by supermarkets and hypermarkets, departmental stores, convenience stores, online channels, and others that are used for home and away from home applications. The facial tissues market research report is one of a series of new reports from The Business Research Company that provides facial tissues market statistics, including facial tissues industry global market size, regional shares, competitors with a facial tissues market share, detailed facial tissues market segments, market trends and opportunities, and any further data you may need to thrive in the facial tissues industry. This facial tissues market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global facial tissues market size will grow from $9.99 billion in 2022 to $10.58 billion in 2023 at a compound annual growth rate (CAGR) of 5.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global facial tissues market size is expected to grow to $12.98 billion in 2027 at a CAGR of 5.2%. The rise in the number of bacterial and viral infectious diseases has led to the rise in demand of sterilized, antibacterial and anti-viral facial tissues. The facial tissues are sterilized during the manufacturing process to prevent the spread of harmful microbes. The special anti-bacterial and antiviral facial tissues are infused with antibacterial and antiviral agents respectively to deactivate the bacteria in cold, flu viruses in cough, sneeze, or nasal discharge to prevent spreading of viruses to others. For instance, Kleenex anti-viral facial tissue manufactured by Kimberly-Clark has three soft layers, including a moisture-activated middle layer that kills 99.9% of cold and flu viruses in the tissue within 15 minutes. Thus, the rise in the number of infectious diseases and increased hygiene awareness among consumers is anticipated to drive the facial tissue market growth by enhancing the utilization of tissue products in the forecast period. The harmful effects caused by the use of chemically manufactured facial tissues can restraint the facial tissue market. The facial tissues are manufactured using different chemical substances. The use of poor- or low-quality chemical ingredients may cause harm to the skin of the consumers. The facial tissues treated with lotions, aromatic agents, antimicrobial agents, dyes and more have appeared in the market during recent years, and thus consumers both children and adults are at a higher risk being exposed to these substances through direct contact, especially with the skin and the mucous membranes, and via inhalation. For instance, facial tissues are often impregnated or infused with aromatic agents such as eucalyptus oils and menthol to alter the aroma and make the nose-blowing experience more pleasant. Hence, the lack of use of good quality of chemical ingredients is anticipated to halt the facial tissues market growth. Companies in the facial tissue market are increasingly using TAD (Through Air Drying) technology to manufacture facial tissues to have cost benefits. The TAD process used in tissue manufacturing was developed by P&G, Kimberly-Clark, and Scott, the machines are being utilized by some manufacturers such as Procter & Gamble for facial tissue production. In TAD process, the fibre web is dewatered and dried by non-compressive means, thereby avoiding the compaction that occurs during wet-pressing of the web in the conventional process. The use of these non-compressive water-removal technologies results in a product with improved properties such as high bulk, softness, cross direction (CD) stretches and absorbency. Fibre savings are possible for TAD tissue as the weight of the sheet can be reduced due to the higher bulk. Since fibre is usually the highest cost element in a tissue product, reduced fibre cost is the major advantage associated with the use of TAD technology. Leading players in the facial tissue paper market are now focusing on improving their production processes by adopting product extension techniques, novel marketing strategies and also making strong investments in R&D into already established factories by adding innovation to these facilities and boosting sales. In February 2020, Cartiere Carrrara, an Italy-based manufacturer of tissue paper products, acquired Carind S.r.l. (Carind) and CRC S.r.l. (CRC) for an undisclosed amount. This acquisition would make it possible for Cartiere Carrara to further solidify its place in the tissue paper sector, which has significant growth potential both in Italy and internationally. Carind S.r.l. (Carind) and CRC S.r.l. (CRC), are European leading manufacturers and distributors of tissue paper products. Major players in the facial tissues market are Kimberly-Clark, Procter and Gamble, APP, Hengan, Vinda, C&S PAPER, Metsa Tissue, WEPA, Cascades, and KP Tissue. Asia-Pacific was the largest region in the facial tissues market in 2022. North America was the second largest region in the global facial tissues market. The regions covered in the global facial tissues market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the facial tissues market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The facial tissues market consists of sales of mineral oil, ceresin, stearyl alcohol, and isopropyl palmitate. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global facial tissues market is segmented - 1) By Type: Box Facial Tissue, Pocket Facial Tissues 2) By Applications: At Home, Away From Home 3) By Distribution Channel: Supermarkets And Hypermarkets, Departmental Stores, Convenience Stores, Online Channels, Other Distribution Channels

Surgical sealants and adhesives are materials used to repair injured tissues and prevent air and fluid leakages during or after surgeries. These are used for minimising blood losses, replacing staples and sutures for better closure, and strengthening wound areas without limiting tissue movement. The surgical sealants and adhesives market covered in this report is segmented by product into biological sealants, synthetic sealants, and semi-synthetic sealants. The biological sealants are made up of biological material that is used to repair injured tissues and prevent air and fluid leakages during or after the surgeries. These are used for various indications such as tissue sealing, tissue engineering, and hemostasis and are used by end-uses such as hospitals, clinics, and others. The surgical sealants and adhesives market research report is one of a series of new reports from The Business Research Company that provides surgical sealants and adhesives market statistics, including surgical sealants and adhesives industry global market size, regional shares, competitors with a surgical sealants and adhesives market share, detailed surgical sealants and adhesives market segments, market trends and opportunities, and any further data you may need to thrive in the surgical sealants and adhesives industry. This surgical sealants and adhesives market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global surgical sealants and adhesives market grew from $2.39 billion in 2022 to $2.63 billion in 2023 at a compound annual growth rate (CAGR) of 9.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The surgical sealants and adhesives market is expected to grow from $3.38 billion in 2027 at a CAGR of 6.5%. The rising number of surgical procedures is predicted to contribute to the growth of the surgical sealants and adhesives market. In recent years, the continuous surge in surgical procedures is registered attributing to the growing prevalence of obesity and other lifestyle diseases, increasing incidence of spinal and sports-related injuries, and rising geriatric population. The old-age population is more prone to chronic, heart, and other diseases, thereby undergoing surgical procedures. According to the World Health Organization, the number of people over the age of 65 is projected to increase from 1 billion in 2020 to 2.1 billion by 2050, globally. The advances in surgical procedures are anticipated to hinder the growth of the surgical sealants and adhesives market. Minimal invasive surgeries are replacing conventional surgical procedures, eliminating complications including bleeding and air leakage and therefore, limiting the use of any surgical sealants and adhesives. According to the American Society of Plastic Surgeons (ASPS), approximately 18 million people undergoing surgical and minimally invasive cosmetic procedures in the USA. Hence, the growing number of minimally invasive surgeries and other substitutes for conventional surgical processes is predicted to impact the growth of the market over the forthcoming years. Several companies operating in the market are focusing on product portfolio expansion into untapped geographies. For instance, in January 2020, Terumo Corporation announced the launch of AQUABRID, a new surgical sealant in the EMEA market. AQUABRID is specially developed for aortic procedures to stop bleeding during and post surgeries. The company earlier introduced this product in Japan under the brand name Hydrofit and is under the process of registration in Eastern Europe, the Middle East, and Africa. In December 2021, Becton, Dickinson and Company, a US-based medical technology company, acquired Tissuemed, Ltd for an undisclosed amount. The acquisition would complete BD’s core portfolio and enable BD to further strengthen the surgical sealants portfolio. Tissuemed is a England-based surgical sealants manufacturer. Major players in the surgical sealants and adhesives market are Baxter International Inc., B. Braun Melsungen AG, Cohera Medical, Inc., CryoLife Inc., C.R. Bard Inc., CSL Limited (CSL Behring), Johnson & Johnson (Ethicon, Inc.), Sanofi, Ocular Therapeutix, Inc., and Sealantis Ltd. North America was the largest region in the surgical sealants and adhesives market in 2022. Western Europe was the second largest region in the global surgical sealants and adhesives market report. The regions covered in the global surgical sealants and adhesives market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the surgical sealants and adhesives report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The patient handling equipment market consists of sales of fibrin sealants, collagen based adhesives, gelatin based adhesives, cyanoacrylates, polymeric hydrogels, and urethane based adhesives. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global surgical sealants and adhesives market is segmented - 1) By Product: Biological Sealants, Synthetic Sealants, Semi-Synthetic Sealants 2) By Indication: Tissue Sealing, Tissue Engineering, Hemostasis 3) By End Use: Hospitals, Clinics, Other End Uses

Cell culture refers to the growth of human, plant, or animal cells in a lab, as well as the growth of microorganisms like bacteria and yeast. Cell cultures can be used for research, medication testing, and infection diagnosis. The cells may come from multicellular eukaryotes, established cell strains, established cell lines, or any combination of these. The main types of cell culture are primary cell culture, secondary cell culture, and cell line. Primary cell cultures are those that develop from tissue explants or specific cells extracted from the source tissue. The different media include natural and artificial ones and are used in stem cell technologies, cancer research, biopharmaceuticals, tissue engineering, regenerative medicine, and others. The cell culture market research report is one of a series of new reports from The Business Research Company that provides cell culture market statistics, including cell culture industry global market size, regional shares, competitors with a cell culture market share, detailed cell culture market segments, market trends and opportunities, and any further data you may need to thrive in the cell culture industry. This cell culture market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cell culture market grew from $22.49 billion in 2022 to $24.94 billion in 2023 at a compound annual growth rate (CAGR) of 10.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cell culture market is expected to grow from $38.18 billion in 2027 at a CAGR of 11.2%. The rise in demand for cell therapy is expected to drive the cell culture market. In cell therapy, viable cells are injected or implanted into a patient's body to cure a medicinal disease. Cell culture is a vital step in any cell-based therapy. According to the Cancer Research Institute (CRI), there are about 1,483 active cell therapies in development in 2020, compared to 1,011 in 2019. Cell culture is used in the development, manufacture, and commercialization of cell therapies and holds the potential to revolutionise the healthcare industry for the treatment of various diseases. Hence, a surge in the demand for cell therapy aids in the growth of the cell culture market. The lack of skilled professionals is expected to hinder the cell culture market’s growth. The consequence of having unskilled workers can also be detrimental to the bottom line of a company, as even a small batch error can cost an organisation millions of dollars. The regulatory agency that issues the facility's licence requires an annual report that includes all failed batches, and if the failure rate is higher than 5%, the plant may be at risk of losing its ability to sell its drug. Furthermore, in February 2022, the U.S. Bureau of Work Statistics estimated that the pandemic cost the labour force close to 8 million skilled-labor positions. In the sectors in charge of the majority of the nation's transportation, construction, and mechanical needs, nearly half of the vacancies have been filled, but about 4 million still exist. The lack of talent is expected to adversely impact the growth of the cell and gene therapy industry, thereby restraining the growth of the cell culture market. The development of products for 3D cell culture by the companies operating in the cell culture market is gaining significant popularity. A 3D cell culture is an artificially created environment in which biological cells are permitted to grow or interact with their surroundings in all three dimensions, similar to how they would in a living organism. For instance, in July 2020, Rigenerand, an Italian company engaged in the production of innovative cell-based technology products for regenerative medicine and oncology, launched a 3D bioreactor called the VITVO handheld bioreactor to offer increased usability, sizing, a closed system, and flexibility for 3D cell culture technologies. Similarly, Jellagen, a UK-based marine biotechnology company, launched JellaGel, a jellyfish collagen hydrogel, suitable for 3D cell culture and tissue engineering. Danaher, a Fortune 500 science and technology company based in the United States, paid $21.4 billion for General Electric Life Sciences' biopharma business in March 2020.As a part of Danaher, the company is to be called Cytiva and will be a standalone operating company within Danaher's Life Sciences segment. GE Biopharma’s offerings included cell culture media, single-use technologies, process chromatography hardware & consumables, development instrumentation and consumables, and service. Major players in the cell culture market are Thermo Fisher Scientific Inc., Corning, Inc., Becton, Dickinson, and Company, Eppendorf AG, Merck KGAA, Lonza Group AG, Sartorius AG, Promocell GmbH, Danaher, and Sartorius. North America was the largest region in the cell culture market in 2022. The Middle East is expected to be the fastest growing region in the global cell culture market during the forecast period. The regions covered in the global cell culture market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cell culture market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The cell culture market includes revenues earned by entities by diagnosing infections, testing new drugs, and conducting research. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain or as part of other products. The global cell culture market is segmented - 1) By Type: Primary Cell Culture, Secondary Cell Culture, and Cell Line 2) By Media: Natural, Artificial 3) By Applications: Stem Cell Technologies, Cancer Research, Biopharmaceutical, Tissue Engineering & Regenerative Medicine, Other Applications

Polymer biomaterials are inert pharmacological substances made up of natural and synthetic origin. The polymer biomaterials are used for enhancing the functionality of tissues and organs that are damaged in various disease therapies. The main types in the polymer biomaterial are silicone rubber, polyester, polymethyl methacrylate (PMMA), polyethylene (PE), polyvinyl chloride, and others. The silicon rubber in polymer biomaterials refers to the rubber matrix that is lightly cross-linked with a polyacrylamide hydrogel and is used for biological and medical purposes. The various nature includes natural and synthetic. The polymer biomaterials are used in cardiovascular, ophthalmology, dental, plastic surgery, wound healing, tissue engineering, orthopedics, neurological disorders / central nervous systems, and others. The polymer biomaterial market research report is one of a series of new reports from The Business Research Company that provides polymer biomaterial market statistics, including polymer biomaterial industry global market size, regional shares, competitors with a polymer biomaterial market share, detailed polymer biomaterial market segments, market trends and opportunities, and any further data you may need to thrive in the polymer biomaterial industry. This polymer biomaterial market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global polymer biomaterial market grew from $55.96 billion in 2022 to $66.45 billion in 2023 at a compound annual growth rate (CAGR) of 18.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The polymer biomaterial market is expected to grow from $126.74 billion in 2027 at a CAGR of 17.5%. Increasing applications of polymeric biomaterials in tissue engineering are driving the global polymer biomaterials market. Polymers are extensively used in regenerative medicine and tissue engineering due to their flexibility and versatile properties such as tailoring the damaged tissue's physical, chemical, and mechanical properties by modification of functional groups during synthesis, according to the regeneration capability of tissues of the organs. Besides being biodegradable, they offer different geometry and structures, thus meeting the needs of specific tissue engineering applications. These growing applications of polymer biomaterial in tissue engineering are expected to drive the market in the forecast period. Stringent regulatory systems concerning the biocompatibility of polymer biomaterials are expected to limit the global polymer biomaterials market. Although biomaterials undergo rigorous premarket evaluations, considerable adverse events and complications are reported regarding the biocompatibility of polymer biomaterials. Biomaterial implantation may result in immunological and inflammatory reactions due to the induction of cellular and molecular events in the host, which may lead to excessive inflammation, impairment of healing, fibrotic encapsulation, tissue destruction, or even isolation and rejection of the implant. To overcome such adverse immune reactions, stringent regulations are imposed by the regulatory authorities, restricting the market growth. Companies in the polymer biomaterial market are increasingly investing in bioresorbable copolymers for medical devices for better performance and long-term stability. Companies such as Evonik have invested in bioresorbable polymers for use in implantable medical devices. The company's copolymer possesses hydrophobic properties of polylactide and hydrophilic properties of polyethylene glycol enabling the degradation rates up to six times faster with added mechanical strength. This innovation enhances biocompatibility, safety, and performance of implantable products, and is applied in the areas of pediatrics and wound closure to accelerate and ease the healing process and provide long-term stability. In January 2020, Mitsubishi Chemical Corporation completed the acquisition of AdvanSource Biomaterials Corporation for $7.25 million. This acquisition is expected to strengthen Mitsubishi’s position within the medical sector and drive its revenues. AdvanSource Biomaterials is a US-based company that manufactures polymer materials that provide critical characteristics in the design and development of medical devices. These polymer biomaterials are used in devices that are designed for treating a broad range of anatomical sites and disease states. Major players in the polymer biomaterials market are BASF, Corbion, Zimmer Biomet, Royal DSM, Koninklijke DSM, Covestro, Evonik Industries, Starch Medical, Victrex, and W. L. Gore and Associate. North America was the largest region in the polymer biomaterials market in 2022. Western Europe was the second largest region in the global polymer biomaterials market report. The regions covered in global polymer biomaterial market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the polymer biomaterials market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and USA. The polymer biomaterials market consists of sales of PCL, PVDF, PLGA, PVP, and nylon. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global polymer biomaterial market is segmented - 1) By Type: Nylon, Silicone Rubber, Polyester, Polymethyl Methacrylate (PMMA), Polyethylene (PE), Polyvinyl Chloride, Other Types 2) By Application: Cardiovascular, Ophthalmology, Dental, Plastic Surgery, Wound Healing, Tissue Engineering, Orthopedics, Neurological Disorders / Central Nervous System, Other Applications 3) By Nature: Natural, Synthetic